ESSA Pharma Inc (EPIX)

[Frankestin]

March 31, September 30,
2023 2022

Cash and cash equivalents $ 44,301 $ 57,076
Prepaids and other assets 114,203 112,429

Total assets $ 158,504 $ 169,505

Current liabilities 2,146 2,310
Long-term debt 20 76
Shareholders' deficiency 156,338 167,119

Total liabilities and shareholders' equity $ 158,504 $ 169,505

March 31, 2023 March 31, 2022 March 31, 2023 March 31, 2022

OPERATING EXPENSES
Research and development $ 4,481 $ 7,649 $ 9,825 $ 13,669
Financing costs 2 4 4 8
General and administration 3,731 3,817 6,250 6,880

Total operating expenses (8,214) (11,470) (16,079) (20,557)

Gain on derivative liability - 118 - 18
Interest and other items 1,155 498 2,279 586

Net loss before taxes (7,059) (10,854) (13,800) (19,953)
Income tax expense (recovery) (2) - (2) 1

Net loss and comprehensive $ (7,061) $ (10,854) $ (13,802) $ (19,952)
loss for the period



Basic and diluted loss per
common share

$ (0.16) $ (0.25) $ (0.31) $ (0.45)